Skip to content
DataLookout
Menu

NCT05300269

SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2022); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 29, 2022 to Jul 5, 2022
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Timeframe: At week 16, DAY1
Percentage of participants with Pathological complete response ( pCR )
Timeframe: At week 16, DAY1

Secondary (6)

Tumor regression grade ( TRG )
Percentage of participants with R0 Resection ( R0 )
Percentage of participants with Clinical complete response ( cCR ) rate.
Event-free survival ( EFS )
Overall survival ( OS )
Show 1 moreShow less
Disease-free survival ( DFS )

Arms and interventions

Perioperative treatmentExperimental

Eligible subjects will receive standard chemoradiotherapy with SHR-1701 followed by XELOX combined with SHR-1701 and surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.

Drugs: SHR-1701;Capecitabine;Oxaliplatin

Sites

1 site in 1 country

  • Fudan University Zhongshan HospitalShanghai, Shanghai Municipality, China